SK pharmteco Announces CGMP Qualification of its Commercial-Scale Viral Vector Manufacturing Facility in France

Contributed by: GlobeNewswire

Tags

viral vector

More Like This

SK pharmteco Boosts Domestic Peptide Scale-Up with Investment in California Facility

PR Newswire associated0

SK pharmteco to showcase its extensive APIs and CGT capabilities in CPHI 2023

SK pharmteco Unites Leading Brands to Create Global Powerhouse in CDMO Services

SK pharmteco Invests $260 Million to Expand Global Small Molecule and Peptide Production

ViroCell Biologics Completes Oversubscribed Financing

ViroCell and Great Ormond Street Hospital Poised to Unlock Clinical Trial ‘Backlog’ Following MHRA Manufacturing Approval

ViroCell Biologics Signs Master Services Agreement With Prominent NCI-Designated Cancer Center

SK pharmteco Achieves Highest-Level My Green Lab Certifications Across Europe and Asia